Troy Wichterman Sells 894 Shares of BioLife Solutions, Inc. (NASDAQ:BLFS) Stock

BioLife Solutions, Inc. (NASDAQ:BLFS) CFO Troy Wichterman sold 894 shares of the stock in a transaction on Wednesday, October 30th. The stock was sold at an average price of $23.15, for a total transaction of $20,696.10. Following the completion of the sale, the chief financial officer now directly owns 123,494 shares of the company’s stock, valued at $2,858,886.10. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Troy Wichterman also recently made the following trade(s):

• On Monday, September 16th, Troy Wichterman sold 611 shares of BioLife Solutions stock. The stock was sold at an average price of $25.12, for a total transaction of $15,348.32.
• On Wednesday, August 21st, Troy Wichterman sold 142 shares of BioLife Solutions stock. The stock was sold at an average price of $25.61, for a total transaction of $3,636.62.

BioLife Solutions Price Performance

BLFS opened at $24.07 on Friday. The company has a fifty day simple moving average of $24.04 and a 200 day simple moving average of $22.16. The firm has a market cap of $1.11 billion, a price-to-earnings ratio of -14.24 and a beta of 1.88. BioLife Solutions, Inc. has a twelve month low of $9.92 and a twelve month high of $26.73. The company has a current ratio of 2.86, a quick ratio of 1.81 and a debt-to-equity ratio of 0.04.

BioLife Solutions (NASDAQ:BLFS) last posted its quarterly earnings data on Thursday, August 8th. The medical equipment provider reported ($0.06) EPS for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.08. BioLife Solutions had a negative net margin of 59.88% and a negative return on equity of 10.75%. The firm had revenue of $28.33 million for the quarter, compared to the consensus estimate of $23.80 million. Equities research analysts expect that BioLife Solutions, Inc. will post -0.36 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in BLFS. Mutual of America Capital Management LLC bought a new position in BioLife Solutions during the 2nd quarter valued at $8,592,000. Vanguard Group Inc. lifted its position in shares of BioLife Solutions by 11.5% in the 1st quarter. Vanguard Group Inc. now owns 2,868,335 shares of the medical equipment provider’s stock worth $53,208,000 after buying an additional 296,727 shares during the last quarter. Raymond James & Associates bought a new position in shares of BioLife Solutions in the 2nd quarter worth about $2,876,000. Envestnet Asset Management Inc. lifted its position in shares of BioLife Solutions by 261.5% in the 2nd quarter. Envestnet Asset Management Inc. now owns 127,215 shares of the medical equipment provider’s stock worth $2,726,000 after buying an additional 92,021 shares during the last quarter. Finally, Fred Alger Management LLC lifted its position in shares of BioLife Solutions by 6.0% in the 2nd quarter. Fred Alger Management LLC now owns 1,579,138 shares of the medical equipment provider’s stock worth $33,841,000 after buying an additional 88,840 shares during the last quarter. 93.24% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on BLFS shares. Northland Securities increased their price objective on shares of BioLife Solutions from $26.00 to $28.00 and gave the stock an “outperform” rating in a research report on Friday, August 9th. TD Cowen increased their price objective on shares of BioLife Solutions from $20.00 to $26.00 and gave the stock a “buy” rating in a research report on Wednesday, July 17th. Craig Hallum raised their price target on shares of BioLife Solutions from $23.00 to $30.00 and gave the company a “buy” rating in a report on Monday, August 12th. Finally, HC Wainwright assumed coverage on shares of BioLife Solutions in a report on Monday, September 30th. They set a “buy” rating and a $29.00 price target for the company. One equities research analyst has rated the stock with a sell rating and six have given a buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $26.67.

About BioLife Solutions

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.